All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Cardiac Progenitor Cells: Hope for the Future

Bharthi R1* and Dhilleswara Rao V2

1Osmania University, Hyderabad, India

2Center for Excellence in Genomics, Madurai Kamaraj University, Tamil Nadu, India

*Corresponding Author:
Bharthi R
Master’s in Pharmacy, Osmania University
Hyderabad, India
E-mail: [email protected]

Received date: 18/07/2016; Accepted date: 18/07/2016; Published date: 25/07/2016

Visit for more related articles at Research & Reviews: Journal of Medical and Health Sciences



The discovery of embryonic and adult stem cells is one of the ground breaking findings, which offer new treatment options for various cardiovascular diseases. Embryonic stem cells can differentiated into multiple cell lineages in vitro such as cardiac myocytes when transplanted into the heart. Few recent studies showed that the infusion of bone marrow-determined cells has remarkable clinical significance and useful advantage. The phase I/II clinical studies have proved that the bone marrow derived mononuclear cells offer variety options; however, their clinical are limited. This review summarizes the role of CPCs in treatment of cardiovascular diseases, clinical opportunities, challenges in usage of CPCs in human models and the future prospective.


Cardiovascular diseases, Embryonic cell, Myocytes, Cardiomyopathy, Cardiac progenitor cells, Cardio spheres.


In recent past, translational approach in clinical medicine led to elucidation of the causes and pathophysiological episodes of heart diseases. The integration of basic knowledge and advanced medical technologies improved the understanding of the causative agents, diagnosis and treatments. Though, significant developments witnessed, cardiovascular diseases are leading cause of mortality. After the introduction of stem cell biology and regenerative medicine, there is an increased interest in Cardiac progenitor cells [1]. Cardiac progenitor cells are endogenous cardiac stem cells (eCSCs) are tissue-specific stem progenitor cells harbored within the adult mammalian heart. A population of inhabitant cardiovascular immature microorganisms, known as cardiogenic forebear cells (CPCs), has been distinguished in the heart. At the present time, it is not known whether the CPCs really home from bone marrow to the heart, or are leftovers of embryonic cell populations that reside in corners in the right chamber and right ventricle. These CPCs are thought to represent the physiological turnover of cardiovascular myocytes and vascular endothelial cells, which happens in the heart without damage [2-10].

Stem cell biology

Cardiogenic progenitor cells contain less than 1% of the cells in the heart, and have been sub classified into c-kit, Scal-1 and Isl-1 cells, as indicated by their look of surface marker translation variables. In any case, none of these surface markers are profoundly particular for heart progenitor cells, since they are additionally found in hematopoietic foundational microorganisms [11]. Also, a blended populace of CPCs, termed cardio spheres, has been recognized from heart biopsies. The presence of each of these cell populaces opens up extra open doors for cardiovascular repair, particularly in patients with ischemic cardiomyopathies.

C-kit cardiogenic stem cells have the limit for self-recharging, clonogenicity and pleuripotency and can separate into myogenic, vascular endothelial and smooth muscle ancestries in vitro and may recover ischemic/infracted myocardium in exploration animals. These cells can express the heart translation variables GATA-4, Nkx2.5 and MEF2, which are essential in the improvement of precardiac cells. C-kit is a receptor for foundational microorganism element, which is discharged from ischemic/ infarcted myocardium and is critical in the chemo attraction of stem cells to the myocardium. Autologous c-kit cells from the privilege atrial member are right now being examined for the treatment of patients with cardiomyopathy in the Cardiac Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) study [12-20].

A second potential populace of CPCs communicates undeveloped cell antigen-1 (Sca-1); however don't express c-kit. Sca- 1 cells have been related to the utilization of mouse Sca-1 immune response, which ties to a homogenous populace of cells in fetal and grown-up human hearts. Sca-1 cells are fit for self-recharging, and are included in cell flagging and cell adhesion. Upon incitement with 5-azacytidine in society, Sca-1 cells express cardiovascular qualities and basic proteins and can separated into cardio myocytes. At the point when directed intravenously, murine Sca-1 cells can home to infarcted myocardium in examination animals (Figure 1) [21].


Figure 1: Cardiac stem cells: A promising treatment option [22].

A third population of human stem cells are found in the hearts of infants, and express the translation element Isl-1, and additionally Nkx2.5 and GATA4, which are vital interpretation variables required in the early phases of cardio genesis. Isl-1 cells don't express c-Kit or Sca-1 [23-40]. These cells can receive a cardio myocyte phenotype with in place calcium cycling and can create activity possibilities when cocultured with neonatal myocytes. The Isl-1 progenitor cells have been disconnected in the atrial divider, conus muscle and right ventricle, and have been involved in the improvement of the right ventricle and the inflow and surge tracts of the heart.

A few laboratories have demonstrated that cardiovascular stem cells can be grown directly from biopsies of atrial and ventricular human tissues, and tissues from examination animals. These foundational microorganisms acquired from heart biopsies are termed cardio spheres. Cardio spheres are a blended populace of heart undifferentiated organisms that are multipotent and clonogenic, and express stem and endothelial begetter cell antigens. These cells can separate into cardio myocytes and vascular cells. Human cardio spheres have been infused into the outskirt zone of myocardial infarcts, and have engrafted and expanded suitable myocardium in exploration animals. Autologous cardio spheres are being researched in the treatment of patients with ischemic cardiomyopathies in the Cardio sphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction (CADUCEUS) study [41].

The presence and accessibility of each of these autologous cardiovascular undeveloped cell populaces, particularly cardio spheres, gives critical new treatment chances to heart repair and constraint of ventricular rebuilding in patients with myocardial areas of dead tissue and ischemic cardiomyopathies. A noteworthy current test is acquiring these cells from heart biopsies without delivering understanding morbidity or mortality (Figure 2).


Figure 2: Schematic illustration of different cardiac resident progenitor cells [64].

In any case, accessibility of cardiac progenitors represents a significant advantage over differentiated cells or undifferentiated pluripotent stem cells to achieve large-scale production of tumor-free cardiac cells for clinical and translational applications [42-63].

MicroRNA and CPCs

As it known that heart has limited regeneration capacity, has become the challenge for the researchers in cell therapy, though CPCs are multipotent myocardium. It has been reported that dysregulation of mir-669 could aberrant the diffraction of CPCc in vitro and in vivo. Further studies proved that in the presence of miRNAs the reprogramming of CSCs were obtained the 3D structures of cardiac muscle in a correct orientation [7,65-69]. Moreover the recent studies showed that the 20 miRNA signatures are useful in predict the myocardial infraction with increased sensitivity, accuracy and specificity. MiRNAs act as an intracellular and intercellular mediator and biomarker in cardiac diseases, which opened the new opportunities in development of new therapeutic strategies. Further clinical studies that could explore the applications and association between CPCs and miRNAs may raise the future hope [16,70].

Conclusion and Future Prospective

Late advances in our comprehension of formative and immature microorganism science of the cardiovascular framework are conveying us nearer to making mammalian heart recovery a clinical reality. This requires well designed clinical tests and validation and must be tested effectively in the model organisms and then in human models. This methodology might be material to various infections for which there are couple of substantial creature model frameworks, for example, complex chromosomal issue, polygenic disarranges where regular hereditary variations present vulnerability or imperviousness to illness, and all around portrayed hereditary issue that are not enough restated in animal models. What's more, medication disclosure, cardio toxicity screening of new medications, and distinguishing proof and approval of helpful targets ought to soon be led straightforwardly on human cardiovascular cells got specifically from patients. Cardiovascular immature microorganism science may well messenger another period of converse translational medication [71-94].